While gastrointestinal AEs such as nausea and vomiting dominate safety reports 8 and recent pharmacovigilance studies highlight increasingly recognized risks including acute pancreatitis, nephritis, hypotension, and syncope 9,10,11 , emerging data suggest that GLP-1 RAs may be associated with neurological adverse events (NAEs) 12,13
Research Means Approved Human trials show that a question was investigated
Subpotent doses may mask true medication response and complicate future dose adjustments or provider assessments
doi: 10.1111/imr.13429 58 LeiSLiuKLiuCAnRBaoZZhangHet al
Numerous studies have highlighted the impact of oxidative stress on MSC differentiation into osteocytes [40] and chondrocytes [41] via the regulation of differentiation signaling cascades [42, 43]
Gross Medicare Part D spending on GLP-1 medications rose roughly fivefold between 2019 and 2024